Overview
Boston Clinical Trials has been recapitalized by Martis Capital via its newly formed clinical research site platform, Alcanza Clinical Research.
Significance
The highly fragmented and rapidly-consolidating clinical research site industry represents a ~$21B global market; nearly 400,000 studies are conducted annually. After the global pandemic further highlighted the importance of clinical research and trials, the market demands more efficient and diverse patient recruitment across a broad range of therapeutic areas and patient populations.
Boston Clinical Trials (BCT) is a leading medical research center based in Boston, MA. BCT works with the top Pharmaceuticals on clinical studies in the areas of Dermatology, Gastroenterology, Internal Medicine, Neurology, Psychiatry, Sexual Dysfunction, and Urology. BCT’s strong reputation for clinical and operational excellence made them the ideal target for Martis Capital’s newly formed clinical research platform, Alcanza Clinical Research.
Crosstree’s Role
Crosstree acted as exclusive financial advisor to Boston Clinical Trials in its recapitalization by Martis Capital through:
- Leveraging market expertise to identify the ideal transaction partner to drive future growth
- Positioning BCT to maximize value
- Managing the due diligence process timeline to bring the transaction to a successful outcome
Latest Deals
Myonex Acquired Creapharm's Clinical & Commercial Packaging and Bioservices Business Units to Expand Clinical Trial Supply Services and Gain of Foothold in Europe
.png)
Myonex Acquired SaveWay Compounding Pharmacy to Expand and Bolster its Clinical Trial Services Across the US
%20(1).png)
physIQ Acquired by Prolaio to Enhance its Next-Gen Connected Heart Care Technology for Clinical Care and Research
.png)
Continuum Clinical, a BC Worldwide company, Acquired by Spectrum Science, a Portfolio Company of Knox Lane, to Bolster Patient Engagement Capabilities
%20(NEW).png)
Yecuris Corporation Acquired by Janvier Group to Expand Preclinical Service Offering Internationally
.png)
Modular Devices, a Portfolio Company of O2 Investment Partners, Partners with Flow Clean Rooms and Supply to Bolster Existing Clean Room Manufacturing Capabilities and Expand Overall Offering
Alpha IRB Acquired by Sabai Global, a Portfolio Company of Thompson Street Capital, to Expand IRB Capabilities
Versiti Acquired Pearl Pathways to Expand Clinical Trial Services Capabilities
VaxTRIALS Acquired by Emmes, a portfolio company of New Mountain Capital, to Expand Vaccine and Clinical Trial Site Capabilities
Grant Avenue Capital Recapitalizes CREO
Monroe Biomedical Research Acquired by New Harbor Capital in a First Step to Build-out a Clinical Research Site Platform
SSI Strategy, a Portfolio Company of Amulet Capital Partners, Acquired NDA Group AB to Bolster Regulatory Affairs Consulting Capabilities and Expand Into the EU
Catalyst Clinical Research, a Portfolio Company of QHP Capital, Acquired Genpro Research to Expand Global Footprint and Deepen Service Offerings
Accel Research Sites Network Acquired by Alcanza Clinical Research, a portfolio company of Martis Capital, to Expand its Clinical Trial Site Network and Clinical Trial Execution Capabilities
Benchmark Research Acquired by IQVIA, combined with Avacare to Expand Vaccine and Clinical Trial Site Capabilities
Clinical Site Services and Patient Advertising Guru Acquired by American Clinical Research Services to Add Tech-Enabled Patient Recruitment Capabilities
ClinChoice Acquires CROMSOURCE to Expand CRO Capabilities Globally
anteris Acquired by Kymanox, a Portfolio Company of Westview Capital Partners, to Expand Injectable Combination Product Development Capabilities Globally
OpenClinica Completes Growth Recapitalization with Thompson Street Capital Partners to Accelerate Enablement of Clinical Trials
